The Canadian Diabetes Association has become Diabetes Canada*
To be used for vascular protection, even if the baseline blood pressure or LDL-C is at target
Does the patient have macrovascular disease?
Does the patient have microvascular disease?
What is the patient’s age?
Does the patient…
The above vascular protective medications have the potential to cause embryopathy: ACEi/ARBs in the 2nd trimester and beyond (controversial effects in the 1st trimester), Statins throughout pregnancy. Therefore, these medications should only be used in the presence of proper preconception counseling and reliable contraception in women of childbearing age. A woman’s pregnancy plans should be discussed at every visit.
Do not use ACEi or ARBs if at high risk of hypotension.
ASA should not be used for the primary prevention of cardiovascular disease in people with diabetes. ASA may be used for secondary prevention.
1 If baseline LDL-C is already ≤ 2.0 mmol/L, target an LDL-C reduction of 50% or more. If baseline LDL-C is not at target, continue dose adjustment or add additional lipid therapy until target is reached.
2 ACE-inhibitor or ARB (angiotensin receptor blocker) should be given at doses that have demonstrated vascular protection (ie. perindopril 8 mg once daily (EUROPA trial), ramipril 10 mg once daily (HOPE trial), telmisartan 80 mg once daily (ONTARGET trial))
Risk Assessment Algorithm:Download PDF
Additional Resources: Canadian Cardiovascular Society (CCS) Guideline Resources
*The Canadian Diabetes Association is the registered owner of the name Diabetes Canada. All content on guidelines.diabetes.ca, CPG Apps and in our online store remains exactly the same. For questions, contact firstname.lastname@example.org.